Approval · Notice of Compliance 31991 · 2023
TEVA-RIVAROXABAN: Notice of Compliance 31991
Issued November 1, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31991
- Date
- November 1, 2023
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- XARELTO (Bayer Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-RIVAROXABAN | 02507196 | Marketed |
| TEVA-RIVAROXABAN | 02507218 | Marketed |
| TEVA-RIVAROXABAN | 02507226 | Marketed |
Medicinal ingredients
- RIVAROXABAN 10 MG per TAB
- RIVAROXABAN 15 MG per TAB
- RIVAROXABAN 20 MG per TAB